ICCC vs RCL · rev $17.5M vs P/E 26, rev $9.28B
ImmuCell Corporation (ICCC) versus Royal Caribbean Cruises Ltd (RCL) — a side-by-side from cached financials, not a winner call.
ImmuCell Corporation (ICCC) is a biotechnology company listed on US.
Royal Caribbean Cruises Ltd (RCL) is a travel services company listed on US.
Latest reported ICCC revenue for 2026-06-30 was $17.5M. Net income was $3.8M. Revenue was up 69.4% from 2026-03-31 to 2026-06-30. ICCC currently screens at market cap $58.9M.
Latest reported RCL revenue for 2026-06-30 was $9.28B. Net income was $2.07B. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
ICCC currently screens at market cap $58.9M. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
Not investment advice. Open the ICCC and RCL stock pages for the full models.
Not investment advice.